|
1
|
Goldschmidt T, Antel J, König FB, Brück W
and Kuhlmann T: Remyelination capacity of the MS brain decreases
with disease chronicity. Neurology. 72:1914–1921. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Patrikios P, Stadelmann C, Kutzelnigg A,
Rauschka H, Schmidbauer M, Laursen H, Sorensen PS, Brück W,
Lucchinetti C and Lassmann H: Remyelination is extensive in a
subset of multiple sclerosis patients. Brain. 129:3165–3172. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cohen JA, Barkhof F, Comi G, Hartung HP,
Khatri BO, Montalban X, Pelletier J, Capra R, Gallo P, Izquierdo G,
et al: Oral fingolimod or intramuscular interferon for relapsing
multiple sclerosis. N Engl J Med. 362:402–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kappos L, Radue EW, O'Connor P, Polman C,
Hohlfeld R, Calabresi P, Selmaj K, Agoropoulou C, Leyk M,
Zhang-Auberson L and Burtin P; FREEDOMS Study Group: A
placebo-controlled trial of oral fingolimod in relapsing multiple
sclerosis. N Engl J Med. 362:387–401. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oo ML, Thangada S, Wu MT, Liu CH,
Macdonald TL, Lynch KR, Lin CY and Hla T: Immunosuppressive and
anti-angiogenic sphingosine 1-phosphate receptor-1 agonists induce
ubiquiti-nylation and proteasomal degradation of the receptor. J
Biol Chem. 282:9082–9089. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mandala S, Hajdu R, Bergstrom J,
Quackenbush E, Xie J, Milligan J, Thornton R, Shei GJ, Card D,
Keohane C, et al: Alteration of lymphocyte trafficking by
sphingosine-1-phosphate receptor agonists. Science. 296:346–349.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matloubian M, Lo CG, Cinamon G, Lesneski
MJ, Xu Y, Brinkmann V, Allende ML, Proia RL and Cyster JG:
Lymphocyte egress from thymus and peripheral lymphoid organs is
dependent on S1P receptor 1. Nature. 427:355–360. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chun J, Weiner JA, Fukushima N, Contos JJ,
Zhang G, Kimura Y, Dubin A, Ishii I, Hecht JH, Akita C, et al:
Neurobiology of receptor-mediated lysophospholipid signaling. From
the first lysophospholipid receptor to roles in nervous system
function and development. Ann NY Acad Sci. 905:110–117. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rao TS, Lariosa-Willingham KD, Lin FF,
Palfreyman EL, Yu N, Chun J and Webb M: Pharmacological
characterization of lysophospholipid receptor signal transduction
pathways in rat cerebrocortical astrocytes. Brain Res. 990:182–194.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Spiegel S and Milstien S:
Sphingosine-1-phosphate: An enigmatic signalling lipid. Nat Rev Mol
Cell Biol. 4:397–407. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Foster CA, Howard LM, Schweitzer A,
Persohn E, Hiestand PC, Balatoni B, Reuschel R, Beerli C, Schwartz
M and Billich A: Brain penetration of the oral immunomodulatory
drug FTY720 and its phosphorylation in the central nervous system
during experimental autoimmune encephalomyelitis: Consequences for
mode of action in multiple sclerosis. J Pharmacol Exp Ther.
323:469–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Choi JW, Gardell SE, Herr DR, Rivera R,
Lee CW, Noguchi K, Teo ST, Yung YC, Lu M, Kennedy G, et al: FTY720
(fingolimod) efficacy in an animal model of multiple sclerosis
requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1)
modulation. Proc Natl Acad Sci USA. 108:751–756. 2011. View Article : Google Scholar :
|
|
13
|
Mullershausen F, Craveiro LM, Shin Y,
Cortes-Cros M, Bassilana F, Osinde M, Wishart WL, Guerini D,
Thallmair M, Schwab ME, et al: Phosphorylated FTY720 promotes
astrocyte migration through sphingosine-1-phosphate receptors. J
Neurochem. 102:1151–1161. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Osinde M, Mullershausen F and Dev KK:
Phosphorylated FTY720 stimulates ERK phosphorylation in astrocytes
via S1P receptors. Neuropharmacology. 52:1210–1218. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun H, Bénardais K, Stanslowsky N,
Thau-Habermann N, Hensel N, Huang D, Claus P, Dengler R, Stangel M
and Petri S: Therapeutic potential of mesenchymal stromal cells and
MSC conditioned medium in Amyotrophic Lateral Sclerosis (ALS) - in
vitro evidence from primary motor neuron cultures, NSC-34 cells,
astrocytes and microglia. PLoS One. 8:e729262013. View Article : Google Scholar :
|
|
16
|
Nicklas W, Baneux P, Boot R, Decelle T,
Deeny AA, Fumanelli M and Illgen-Wilcke B; FELASA (Federation of
European Laboratory Animal Science Associations Working Group on
Health Monitoring of Rodent and Rabbit Colonies): Recommendations
for the health monitoring of rodent and rabbit colonies in breeding
and experimental units. Lab Anim. 36:20–42. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pébay A, Toutant M, Prémont J, Calvo CF,
Venance L, Cordier J, Glowinski J and Tencé M:
Sphingosine-1-phosphate induces proliferation of astrocytes:
Regulation by intracellular signalling cascades. Eur J Neurosci.
13:2067–2076. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yoshida Y, Nakada M, Sugimoto N, Harada T,
Hayashi Y, Kita D, Uchiyama N, Hayashi Y, Yachie A, Takuwa Y, et
al: Sphingosine-1-phosphate receptor type 1 regulates glioma cell
proliferation and correlates with patient survival. Int J Cancer.
126:2341–2352. 2010.
|
|
19
|
Sheridan GK and Dev KK: S1P1 receptor
subtype inhibits demyelination and regulates chemokine release in
cerebellar slice cultures. Glia. 60:382–392. 2012. View Article : Google Scholar
|
|
20
|
Van Doorn R, Van Horssen J, Verzijl D,
Witte M, Ronken E, Van Het Hof B, Lakeman K, Dijkstra CD, Van Der
Valk P, Reijerkerk A, et al: Sphingosine 1-phosphate receptor 1 and
3 are upregulated in multiple sclerosis lesions. Glia.
58:1465–1476. 2010.PubMed/NCBI
|
|
21
|
Wu C, Leong SY, Moore CS, Cui QL, Gris P,
Bernier LP, Johnson TA, Séguéla P, Kennedy TE, Bar-Or A, et al:
Dual effects of daily FTY720 on human astrocytes in vitro:
Relevance for neuroinflammation. J Neuroinflammation. 10:412013.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Yamagata K, Tagami M, Torii Y, Takenaga F,
Tsumagari S, Itoh S, Yamori Y and Nara Y: Sphingosine 1-phosphate
induces the production of glial cell line-derived neurotrophic
factor and cellular proliferation in astrocytes. Glia. 41:199–206.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bauer J, Berkenbosch F, Van Dam AM and
Dijkstra CD: Demonstration of interleukin-1 beta in Lewis rat brain
during experimental allergic encephalomyelitis by
immunocytochemistry at the light and ultrastructural level. J
Neuroimmunol. 48:13–21. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Merrill JE: Tumor necrosis factor alpha,
interleukin 1 and related cytokines in brain development: Normal
and pathological. Dev Neurosci. 14:1–10. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herx LM, Rivest S and Yong VW: Central
nervous system-initiated inflammation and neurotrophism in trauma:
IL-1 beta is required for the production of ciliary neurotrophic
factor. J Immunol. 165:2232–2239. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mason JL, Suzuki K, Chaplin DD and
Matsushima GK: Interleukin-1beta promotes repair of the CNS. J
Neurosci. 21:7046–7052. 2001.PubMed/NCBI
|
|
27
|
Arenas E, Trupp M, Akerud P and Ibáñez CF:
GDNF prevents degeneration and promotes the phenotype of brain
noradrenergic neurons in vivo. Neuron. 15:1465–1473. 1995.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Henderson CE, Phillips HS, Pollock RA,
Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA
and Simpson LC; Simmons L, et al: GDNF: A potent survival factor
for motoneurons present in peripheral nerve and muscle. Science.
266:1062–1064. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lin LF, Doherty DH, Lile JD, Bektesh S and
Collins F: GDNF: A glial cell line-derived neurotrophic factor for
midbrain dopa-minergic neurons. Science. 260:1130–1132. 1993.
View Article : Google Scholar : PubMed/NCBI
|
